Global Breast Cancer Liquid Biopsy Market - 2024 - 2031

Report Overview

The Global Breast Cancer Liquid Biopsy Market reached US$ 1.6 billion in 2023 and is expected to reach US$ 7.98 billion by 2031, growing at a CAGR of 23.2% during the forecast period 2024-2031.

A liquid biopsy is a laboratory test done on a sample of blood, urine, or other body fluid to look for cancer cells from a tumor or small pieces of DNA, RNA, or other molecules released by tumor cells into a person's body fluids. Liquid biopsy allows multiple samples to be taken over time, which may help doctors understand what kind of genetic or molecular changes are taking place in a tumor. A liquid biopsy may be used to help find cancer at an early stage. It may also be used to help plan treatment or to find out how well treatment is working or if cancer has come back.

It is composed of different biological matrices such as circulating tumor cells (CTCs), cell-free nucleic acids, exosomes or tumors "educated platelets." Recent technological and molecular advances, greatly facilitated by the use of microfluidics in many cases, have permitted large progress in both the ability to purify and analyze liquid biopsy components.

Market Dynamics: Drivers

Increasing prevalence of breast cancer

The demand for the breast cancer liquid biopsy market is driven by multiple factors. The rising prevalence of breast cancer propels the market growth.

Furthermore, the demand for treatment will be fueled by the increase in awareness among people and technological advancements. For instance, according to uicc.org, Breast cancer is the most diagnosed cancer among women worldwide and is the most diagnosed cancer in women in 157 countries, accounting for 1 in 4 cancer cases. It is the second most frequent cancer amongst both sexes and is the leading cause of death from cancer in women. With the estimated 2.3 million new cases of breast cancer in 2022, roughly one in every 9 cancers for both sexes diagnosed globally was breast cancer. In 2022, there were an estimated 669,418 deaths from breast cancer, with a disproportionate number of these deaths occurring in low-resource settings.

Moreover, according to breastcancer.org, About 66% of breast cancer cases are diagnosed at a localized stage before cancer has spread outside of the breast when it is easiest to treat. There are currently more than four million women with a history of breast cancer in the US.

Moreover, according to an article posted by WHO in February 2023, there are more than 2.3 million cases of breast cancer that occur each year, which makes it the most common cancer among adults. In 95% of countries, breast cancer is the first or second leading cause of female cancer deaths. Yet, survival from breast cancer is widely inequitable between and within countries nearly 80% of deaths from breast and cervical cancer occur in low- and middle-income countries.

Restraints

Factors such as high costs associated with liquid biopsy, the shortage of skilled professionals, and stringent regulatory requirements for the approval of new treatments are expected to hamper the market.

Market Segment Analysis

The global breast cancer liquid biopsy market is segmented based on product type, circulating biomarkers, application, end-user, and region.

The segment circulating tumor cells (CTCs) accounted for approximately 47.9% of the global breast cancer liquid biopsy market share

The circulating tumor cells segment is expected to hold the largest market share over the forecast period. In this segment, the technological advancements, and rising funds for private manufacturers for research work would drive this market.

Circulating tumor cells (CTCs) as a liquid biopsy have great potential in clinical applications and basic cancer research. Liquid biopsy, a minimally invasive technique, allows for the detection of cancer biomarkers directly from bodily fluids. Among these biomarkers, CTCs, cell-free DNA (cfDNA), and RNA provide a dynamic glimpse into the tumor's genetic landscape. This revolutionary approach offers promising avenues for early cancer detection, monitoring disease progression, and tailoring personalized treatment strategies.

CTCs are now recognized as crucial players in the metastatic process. Their detection and analysis have paved the way for the development of liquid biopsy techniques, offering a minimally invasive alternative to traditional tissue biopsies. This innovative approach has revolutionized our understanding of tumor dynamics, enabling real-time monitoring and providing insights into tumor heterogeneity, treatment response, and disease progression.

Market Geographical Analysis

North America accounted for approximately 42.8% of the global breast cancer liquid biopsy market share

North America region is expected to hold the largest market share over the forecast period. The rising incidence of breast cancer, and growing awareness among people, in this region, help to propel the market.

For instance, according to breastcancer.org, approximately 13% (about one in eight) of U.S. women will develop invasive breast cancer in the course of their life. In recent years, incidence rates have increased slightly by 0.5% per year. Breast cancer is still one of the leading causes of cancer-related death in U.S. women, second only to lung cancer. Breast cancer is the most commonly diagnosed cancer among U.S. women after skin cancers. Each year, about 30% of all newly diagnosed cancers in women are breast cancer. There are currently more than four million women with a history of breast cancer in the US.

Moreover in June 2023, Labcorp launched liquid biopsy to detect cancer-related biomarkers. The Plasma Focus liquid biopsy requires only a standard blood draw to run. It looks through the sample for bits of cell-free DNA (cfDNA) that are released by tumor cells into the bloodstream and that may offer insights into the cancer treatments that'll work most effectively for a specific patient.

Market Segmentation

By Product Type

Reagents & Kits

Instruments

By Circulating Biomarkers

Circulating Tumor Cells (CTCs)

Circulating Cell-free DNA (cfDNA)

Extracellular Vesicles (EVs)

Others

By Application

Early Screening

Treatment Selection

By End-User

Hospitals

Diagnostic Centers

Research and Educational Institutions

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the global breast cancer liquid biopsy market include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott, Agilent Technologies Inc., Merck KGaA, Cell Signaling Technology Inc., Medtronic, Bio-Rad Laboratories Inc., ExoDx, and Biocept Inc. among others.

Key Developments

On September 2023, nRichDX(R) launched its new RUO-labeled CTC enrichment kit that uniquely isolates Circulating Tumor Cells (CTCs) from up to 40mL of whole blood samples to help researchers advance liquid biopsy assay research and development.

Why Purchase the Report?

To visualize the global breast cancer liquid biopsy market segmentation based on product type, circulating biomarkers, application, end-user, and region, as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development

Excel data sheet with numerous data points of global breast cancer liquid biopsy market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping is available in Excel consisting of key products of all the major players.

The global breast cancer liquid biopsy market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies